Former Eircom finance director Peter Lynch dies aged 63
The one-time stockbroker from Belfast was considered dynamic and gregarious
Irish biotech Amarin gears up for drug launch in Europe
Company’s cardiovascular drug should be cleared in next six weeks for EU use
Irish heart drug group Amarin slumps 70% over patent suit loss
Nevada court rules patents are invalid in crunch battle with generic rivals
Irish pharma group says sales of heart drug will top projections
Amarin doubling size of US sales force as FDA sanctions expanded market for Vascepa
Amarin secures approval for heart drug Vascepa in Canada
Irish pharma group gearing up for legal battle over patents with generic drugmakers
Winners and losers in a year of extremes in the business world
Green Reit and CRH among winners as Boeing, Denis O’Brien and RTÉ join losers
Amarin secures European review for cardio drug Vascepa
Purified fish oil drug has been recommended by FDA for wider market approval
Amarin president named US EY Entrepreneur of the Year for life sciences
John Thero, CEO of fish-oil drug specialist, accepts award for Irish-domiciled company
No home run yet for Amarin’s heart drug Vascepa
Cantillon: Unanimous FDA panel backing hides differences in view over potential
Amarin shares jump as FDA panel backs heart drug
US regulator’s advisory committee backs dramatic increase in market for purified fish oil drug Vascepa
Roll up, roll up: capitalism will drive cannabis legalisation in Ireland
Legalisation is coming, no matter what Irish policymakers may say now
Tariff threats to EU goods do little to curb gains in European share
BoI and Aryzta drag Iseq lower but Ryanair goes higher
Shares jump 15% in Ireland’s Amarin on hopes for heart drug
Strong increase in proft forecast on the back of sales of fish oil drug in the US
Amarin president named EY Entrepreneur of the Year
John Thero of the fish oil drug specialist recognised for company’s drug, Vascepa
Amarin jumps on FDA priority review for heart drug
Irish company’s Vascepa on track for earlier than expected approval
Irish VC group Fountain Healthcare Partners raises €118m
Group beats €100m target and intends to invest the bulk of the fund in Europe and US
Amarin’s heartwarming bulletin for firm’s shareholders
Stock advances over fivefold in 12 months on evidence of medicine’s cardiovascular effect
Amarin to seek European approval for heart drug Vascepa
Clinical trials show Irish company’s fish-oil drug cut incidence of heart attacks and strokes
Dalata named company of the year at ‘Irish Times’ business awards
The Republic’s largest hotel group has more than 9,000 rooms across its portfolio
The Irish Times Company of the Year: the four finalists
Stripe, Dalata, Glanbia and Amarin shortlisted on back of standout years
Business 2018: the winners and the losers
The last 12 months proved to be another year of mixed fortunes in corporate Ireland
Irish firm Amarin confirms heart drug success
Some concern over neutrality of placebo and whether it might have boosted Vascepa data
Tetrarch buys 470 acres of Howth, bankers’ bonuses and Ryanair’s turbulent week
‘Business Today: the best news, analysis and comment from ‘The Irish Times’ business desk
Amarin – an overnight success 10 years in the making
After several false starts, way is clear for John Thero to take Vascepa cholesterol drug to market
Amarin surges as trial results exceed expectations
Company’s Vascepa drug proves effective in reducing risk from stroke and heart attack
Taoiseach defends relationship with chair of firm that HSE chief has joined
Varadkar backs Minister’s consent granted to O’Brien to take up board role at US firm
Amarin reports 59% jump in sales for Vascepa drug
Irish biotech’s drug used to treat US patients with high levels of blood fats
52 Places to Go in 2017
There are thousands of getaways waiting to be explored. Here are some ideas to get you started
Amarin reports strong sales growth for Vascepa
Company targets expanded market share for fish oil drug that cuts risk of heart disease
Amarin reports 62% rise in fourth quarter sales of Vascepa
Costs, including ongoing R&D, means the company reports loss of $21.9 million for the quarter and $115.2 million for full year
Drug minnow Amarin downs FDA in constitutional battle
Irish pharma firm wins major victory over FDA on off-label promotion of its drug Vascepa
Irish drug company Amarin defeats FDA in US lawsuit
US court rules regulator cannot bar company promoting off label use for drug
Cantillon: Amarin faces down the mighty FDA
Small Irish pharma group sues US regulator over restricting its right to free speech
Pharma group Amarin sues FDA over right to brief doctors on drug
Dublin group says regulator refusal to allow it discuss off label use breaches US first amendment rights and puts it at a disadvantage to rival unregulated products
Amarin secures $52.8m to promote cardiovascular drug
Irish pharmaceuticals group says it raised the capital through new and existing investors
Amarin slumps more than 20 per cent as drug appeal rejected
Regulator shuts door on plans to extend market for Vascepa
Amarin takes legal action against FDA over patent protection for Vascepa
Company continues to fight regulator as it reports $166m loss in first year of commercial operation for fish oil drug
Amarin slides on latest FDA setback
US health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood fat-lowering drug
Amarin raises doubts over future prospects
Drug firms questions whether it can afford to fund trial central to growth plans
Cantillon: Amarin in need of serious medicine
Company to slash staff numbers in an effort to curb operating costs.
Amarin shares slump on FDA panel rejection
Company fails to persuade advisory panel to back exponential expansion of market for cardiovascular drug
Amarin fails to secure backing of FDA panel for expanded use
FDA is scheduled to decide whether to clear the drug for wider use by December 20th
Cantillon: Amarin tests FDA appetite for fish oil drug
Stock value suggests even its proponents are not entirely sure of their ground
Amarin shares hit by ruling on generic drugs
Victory by Teva and Par in US case raises concern over prospects for cholesterol drug
Losses at Amarin widen despite strong revenues from new drug
Irish biopharma group regonised revenues of $5.5m from its new Vascepa drug in Q2
Amarin announces plan to sell another 21.7 million shares
Proceeds will fund ongoing rollout of Vascepa fish oil drug in the US
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices